middle.news
Actinogen’s Alzheimer’s Trial Clears Safety Hurdle, Eyes January Efficacy Review
11:21am on Wednesday 12th of November, 2025 AEDT
•
Biotechnology
Read Story
Actinogen’s Alzheimer’s Trial Clears Safety Hurdle, Eyes January Efficacy Review
11:21am on Wednesday 12th of November, 2025 AEDT
Key Points
Independent Data Monitoring Committee endorses continuation without changes
Safety data reviewed from 153 participants in XanaMIA trial
Efficacy data not yet evaluated; interim analysis planned for January 2026
Trial aims to enrol 220 patients with mild to moderate Alzheimer’s disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACW
OPEN ARTICLE